Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients

Leukemia Research

Volumn 36, Issue 2, 2012, Pages 182-185

  Rigacci, Luigi ^a   Landi, Carla ^a   Caruso, Jean Pierre ^a   Puccini, Benedetta ^a   Alterini, Renato ^a   Carrai, Valentina ^a   Perrone, Tania ^b   Bosi, Alberto ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Italfarmaco SpA   (Italy)

Author keywords

ABVD regimen; Chemotherapy induced nausea and vomiting (CINV); Hodgkin Lymphoma

Indexed keywords

BLEOMYCIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; LAXATIVE; METOCLOPRAMIDE; PALONOSETRON; SENNA EXTRACT; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HODGKIN DISEASE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VINBLASTINE; VOMITING; YOUNG ADULT;

EID: 84855189204     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.06.025     Document Type: Article

References (31)

1. Hesketh P.J. Chemotherapy-induced nausea vomiting. N Engl J Med 2008, 358:2482-2494.
2. Roila F., Herrstedt J., Aapro M., Gralla R.J., Einhorn L.H., Ballatori E., et al. Guidelines update for MASCC and ESMO in the prevention of chemohterapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21(Suppl. 5):v232-v243. 10.1093/annonc/mdq194.
3. Antiemesis (2011) NCCN clinical practice guidelines in oncology. V.3., ; 2011 [accessed 04.05.11]. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
4. Bonadonna G., Zucali R., Monfardini S., De Lena M., Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36(1):252-259.
5. Hesketh P.J., Kris M.G., Grunberg S.M., et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997, 15:103-109.
6. Rueda A., Alba E., Ribelles N. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study. J Clin Oncol 1997, 15(3):1118-1122.
7. Federico M., Luminari S., Iannitto E., Polimeno G., Marcheselli L., Montanini A., et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's Lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi trial. J Clin Oncol 2009, 27(5):805-811.
8. Gobbi P.G., Levis A., Chisesi T. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's Lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005, 23(36):9198-9207.
9. Roila F., Tonato M., Cognetti F., Cortesi E., Favalli G., Marangolo M., et al. Prevention of cisplatin-induced emesis: a double-blind multicenter, randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991, 9:675-678.
10. Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995, 332:1-5. Italian Group for Antiemetic Research.
11. Herrstedt J., Aapro M.S., Smyth J.F., Del Favero A. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 1998, 6:204-214.
12. Allan S.G., Cornbleet M.A., Warrington P.S., Golland I.M., Leonard R.C., Smyth J.N. Dexamethasone high-dose metoclopramide: efficacy in controlling cisplatin-induced nausea vomiting. BMJ 1984, 289:878-879.
13. Roila F., Tonato M., Ballatori E., Del Favero A. Comparative studies of various antiemetic regimens. Support Care Cancer 1996, 4:270-280.
14. Geling O., Eichler H.-G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005, 23:1289-1294.
15. Yang L.P., Scott L.J. Palonosetron: in the prevention of nausea and vomiting. Drugs 2009, 69(16):2257-2278.
16. Eisenberg P., Figuero-Vadillo J., Zamora R., Charu V., Hajdenberg J., Cartmell A, et al. Improved prevention of moderately emetogenic chemotherapy induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist results of a phase III, single dose trial versus dolasetron. Cancer 2003, 98(11):2473-2482.
17. Gralla R., Lichinitser M., Van Der Vegt S., Sleeboom H., Mezger J., Peschel C., et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003, 14:1570-1577.
18. Aapro M.S., Grunberg S.M., Manikhas G.M., et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006, 17(9):1441-1449.
19. Rubenstein E.B., Gralla R.J., Eisenberg P. Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) Combined results of two Phase III trials. Proc Am Soc Clin Oncol 2003, 22(729):A2932.
20. Saito M., Aogi K., Sekine I., Yoshizawa H., Yanagita Y., Sakai H., et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009, 10(2):115-124.
21. Decker G.M., DeMeyer E.S., Kisko D.L. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006, 4:35-41.
22. Wong E.H.F., Clark R., Leung E., Loury D., Bonhaus D.W., Jakeman L., et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995, 114:851-859.
23. Stoltz R., Cyong J.C., Shah A., Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004, 44:520-531.
24. Thompson A.J., Lummis S.C. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 2007, 11:527-540.
25. Rojas C., Stathis M., Thomas A.G., Massuda E.B., Alt J., Zhang J., et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008, 107:469-478.
26. Rojas C., Thomas A.G., Jesse A., Stathis M., Zhang J., Rubenstein E.B., et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010, 626(2-3):193-199.
27. Bonadonna G., Santoro A., Bonfante V., Valagussa P. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. Cancer Treat Rep 1982, 66(April (4)):881-887.
28. Grunberg S.M. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 2007, 18:233-240.
29. Vardy J., Chiew K.S., Galica J., Pond G.R., Tannock I.F. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006, 94:1011-1015.
30. Aapro M., Fabi A., Nolè F., Medici M., Steger G., Bachmann C., et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010, 21(May (5)):1083-1088.
31. Celio L., Frustaci S., Denaro A., Buonadonna A., Ardizzoia A., Piazza E., et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2010.